{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:41:57Z","timestamp":1790797317061,"version":"4.1.0"},"reference-count":30,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Geriatrics"],"abstract":"<jats:p>Background\/Objectives: Type 2 diabetes (T2D) and chronic kidney disease (CKD) frequently coexist in older adults. Sodium\u2013glucose cotransporter-2 inhibitors (SGLT2i) are recommended for renal and heart protection, yet their use in routine care remains inconsistent. We aimed to investigate differences in SGLT2i prescribing between regional and university hospital settings and assess whether such disparities persist after accounting for patient characteristics. Methods: In this retrospective analysis, patients were stratified by follow-up site (regional vs. university hospital). The primary outcome was SGLT2i use. Logistic regression models were adjusted for strong determinants of prescribing decisions, including age, sex, hypertension, dyslipidemia, heart failure, and estimated glomerular filtration rate. We tested the robustness of the results using additional analyses, including exclusion of frail patients and adjustment with propensity score methods, such as matching and inverse probability weighting (IPTW). Results: The study included 135 patients, of whom 80 were followed at the regional hospital and 55 at the university hospital. SGLT2i use was significantly lower in the regional setting (27.5% vs. 63.6%, p &lt; 0.001). In adjusted models, university follow-up remained strongly associated with SGLT2i prescription [odds ratio 3.60, 95% confidence interval (CI) 1.61\u20138.03, p = 0.0018]. IPTW demonstrated 4.40-fold higher odds of SGLT2i use in the university hospital setting (95% CI 2.07\u20139.36, p &lt; 0.001). Conclusions: These findings indicate that the lower use of SGLT2i among older adults with T2D and CKD followed in regional hospitals may reflect patterns consistent with clinical inertia, underscoring the importance of efforts to promote equitable and guideline-aligned prescribing practices across levels of care.<\/jats:p>","DOI":"10.3390\/geriatrics10060144","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T10:08:51Z","timestamp":1762423731000},"page":"144","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Clinical Inertia in SGLT2 Inhibitor Use Among Elderly Patients with Type 2 Diabetes and Chronic Kidney Disease: A Comparison of Regional and University Hospital Practice"],"prefix":"10.3390","volume":"10","author":[{"given":"Kyriaki","family":"Vafeidou","sequence":"first","affiliation":[{"name":"School of Medicine, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ourania","family":"Psoma","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Ioannina, 45110 Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Apostolidis","sequence":"additional","affiliation":[{"name":"School of Medicine, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Sarvani","sequence":"additional","affiliation":[{"name":"School of Medicine, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Doumas","sequence":"additional","affiliation":[{"name":"School of Medicine, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2376-740X","authenticated-orcid":false,"given":"Kalliopi","family":"Kotsa","sequence":"additional","affiliation":[{"name":"School of Medicine, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1708-3415","authenticated-orcid":false,"given":"Vasileios","family":"Tsimihodimos","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Ioannina, 45110 Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5853-1352","authenticated-orcid":false,"given":"Theocharis","family":"Koufakis","sequence":"additional","affiliation":[{"name":"School of Medicine, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41574-022-00690-7","article-title":"The burden and risks of emerging complications of diabetes mellitus","volume":"18","author":"Tomic","year":"2022","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"120","DOI":"10.4239\/wjd.v8.i4.120","article-title":"Type 2 diabetes and quality of life","volume":"8","author":"Trikkalinou","year":"2017","journal-title":"World J. Diabetes"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S2213-8587(21)00113-3","article-title":"Treatment of type 2 diabetes: Challenges, hopes, and anticipated successes","volume":"9","author":"Nauck","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s40265-024-02091-8","article-title":"Slowing the progression of chronic kidney disease in patients with type 2 diabetes using four pillars of therapy: The time to act is now","volume":"84","author":"Georgianos","year":"2024","journal-title":"Drugs"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2012070718","article-title":"Kidney disease and increased mortality risk in type 2 diabetes","volume":"24","author":"Afkarian","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_6","first-page":"e33509","article-title":"Underprescription of SGLT2i and GLP-1 RA: CAREPRO-T2D cross-sectional study","volume":"15","author":"Lopes","year":"2023","journal-title":"Cureus"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1080\/17512433.2023.2247977","article-title":"Sodium-glucose cotransporter 2 inhibitors in frail, older people with type 2 diabetes and heart failure: Do we have enough evidence to confidently support the use?","volume":"16","author":"Koufakis","year":"2023","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4103\/0250-474X.102545","article-title":"Assessment of drug\u2013drug interactions among renal failure patients of nephrology ward in a South Indian tertiary care hospital","volume":"74","author":"Rama","year":"2012","journal-title":"Indian J. Pharm. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"afad254","DOI":"10.1093\/ageing\/afad254","article-title":"Sodium-glucose cotransporter-2 inhibitors in frail or older people with type 2 diabetes and heart failure: A systematic review and meta-analysis","volume":"53","author":"Aldafas","year":"2024","journal-title":"Age Ageing"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.diabres.2005.03.029","article-title":"Comparison of the quality of diabetes care in primary care diabetic clinics and general practice clinics","volume":"70","author":"Sequeira","year":"2005","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Almigbal, T.H., Alzarah, S.A., Aljanoubi, F.A., Alhafez, N.A., Aldawsari, M.R., Alghadeer, Z.Y., and Alrasheed, A.A. (2023). Clinical inertia in the management of type 2 diabetes mellitus: A systematic review. Medicina, 59.","DOI":"10.3390\/medicina59010182"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Kaewbut, P., Kosachunhanun, N., Phrommintikul, A., Chinwong, D., Hall, J.J., and Chinwong, S. (2021). Effect of clinical inertia on diabetes complications among individuals with type 2 diabetes: A retrospective cohort study. Medicina, 58.","DOI":"10.3390\/medicina58010063"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Vafeidou, K., Psoma, O., Dimakopoulos, G., Apostolidis, E., Sarvani, A., Gavriilaki, E., Doumas, M., Tsimihodimos, V., Kotsa, K., and Koufakis, T. (2025). Evaluating guideline alignment by analyzing patient profiles of elderly people with type 2 diabetes and chronic kidney disease treated or not with SGLT2 inhibitors. Pharmaceuticals, 18.","DOI":"10.3390\/ph18060807"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2024). KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int., 105, S117\u2013S314.","DOI":"10.1016\/j.kint.2023.10.018"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee (2025). 9. Pharmacologic approaches to glycemic treatment: Standards of care in diabetes\u20142025. Diabetes Care, 48, S181\u2013S206.","DOI":"10.2337\/dc25-S009"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/pds.1104","article-title":"Regional variation in the prescribing for diabetes and use of secondary preventative therapies in Ireland","volume":"14","author":"Usher","year":"2005","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"296","DOI":"10.4103\/ijem.ijem_119_23","article-title":"Clinical inertia: A wider perspective and proposed classification criteria","volume":"27","author":"Raveendran","year":"2023","journal-title":"Indian J. Endocrinol. Metab."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12933-017-0622-7","article-title":"Translating recent results from the cardiovascular outcomes trials into clinical practice: Recommendations from the Central and Eastern European Diabetes Expert Group","volume":"16","author":"Schernthaner","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.mayocpiqo.2017.07.003","article-title":"Influence of referral to a combined diabetology and nephrology clinic on renal functional trends and metabolic parameters in adults with diabetic kidney disease","volume":"1","author":"Martin","year":"2017","journal-title":"Mayo Clin. Proc. Innov. Qual. Outcomes"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"108310","DOI":"10.1016\/j.diabres.2020.108310","article-title":"Effect of clinical inertia and trial participation in younger and older adults with diabetes having comorbidities and progressive complications","volume":"166","author":"Strain","year":"2020","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Gittus, M., O\u2019Cathain, A., Miller, K., Oklopcic, A., Ong, A.C., and Fotheringham, J. (2025). A conceptual model of factors potentially influencing prescribing decisions for chronic conditions: An overview of systematic reviews. BMC Med., 23.","DOI":"10.1186\/s12916-025-04194-9"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s12933-022-01631-4","article-title":"Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in Central and Eastern Europe: Retrospective cross-sectional and longitudinal evaluations in the CORDIALLY study","volume":"21","author":"Suplotova","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"20543581231217857","DOI":"10.1177\/20543581231217857","article-title":"Identifying barriers and facilitators for increasing uptake of sodium-glucose cotransporter-2 inhibitors in British Columbia, Canada, using the Consolidated Framework for Implementation Research","volume":"11","author":"Yi","year":"2023","journal-title":"Can. J. Kidney Health Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e2852","DOI":"10.1210\/clinem\/dgaf301","article-title":"Overcoming disparities in using SGLT2 inhibitors for cardiorenal protection in persons with and without type 2 diabetes","volume":"110","author":"Jack","year":"2025","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1080\/14740338.2024.2354885","article-title":"Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit\u2013safety profile","volume":"23","author":"Scheen","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/dom.12626","article-title":"Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin","volume":"18","author":"Khunti","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1007\/s12325-024-02957-z","article-title":"Early identification and management of chronic kidney disease: A narrative review of the crucial role of primary care practitioners","volume":"41","author":"Kushner","year":"2024","journal-title":"Adv. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Santana, R., Umana, C.D., Oo, Z.T., Kolli, S.T., Bejugam, V.R., Piplani, S., Aljareh, A., Garcia, B.T., Raptis, D., and Asuzu, C. (2025). Optimizing guideline-directed medical therapy in chronic kidney disease and type 2 diabetes mellitus patients in primary care. Am. J. Med., in press.","DOI":"10.1016\/j.amjmed.2025.08.029"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.2337\/diacare.25.11.1946","article-title":"Impact of a program to improve adherence to diabetes guidelines by primary care physicians","volume":"25","author":"Kirkman","year":"2002","journal-title":"Diabetes Care"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"7591","DOI":"10.2147\/IJGM.S333501","article-title":"Barriers to Clinical Practice Guideline Implementation among Physicians: A Physician Survey","volume":"14","author":"Qumseya","year":"2021","journal-title":"Int. J. Gen. Med."}],"container-title":["Geriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2308-3417\/10\/6\/144\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T10:38:53Z","timestamp":1762425533000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2308-3417\/10\/6\/144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":30,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["geriatrics10060144"],"URL":"https:\/\/doi.org\/10.3390\/geriatrics10060144","relation":{},"ISSN":["2308-3417"],"issn-type":[{"value":"2308-3417","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]}}}